Abstract 1634P
Background
Molecular profiling is increasingly implemented to guide treatment of pancreatic ductal adenocarcinoma (PDAC), especially if enrolment in clinical trials is considered. The aim of our study was to describe actionable alterations detected in KRAS mutant (KRASm) versus KRAS wild-type (KRASwt) PDAC, as the latter is considered as harboring more molecular alterations.
Methods
This monocentric prospective study included patients with locally advanced or metastatic PDAC who underwent next-generation sequencing (NGS) on liquid biopsy and/or tissue sample between 2015 and 2022 (FoundationOne® CDx, Liquid CDx or Oncomine Comprehensive Assay), as part of the BIP study (NCT02534649).
Results
233 patients with a PDAC underwent NGS: 63 on tissue samples alone, 95 on liquid biopsies alone, and 75 on both tissue and liquid. Among 170 liquid biopsies, 90 were informative (52.9%). Among 196 patients with informative NGS, 172 patients (87.8%) had a KRASm PDAC, and 24 a KRASwt PDAC (12.2%). Median overall survival (OS) in the KRASwt group was 27.8 versus 20.3 months for KRASm patients (HR 0.58, CI (0.39-0.87), p=0.02). ESCAT alterations were found in 17.3% of total population, 25.0% in KRASwt group and 16.3% in KRASm group. All 7 BRCA1/2 germline mutations were detected in the KRASm group. 1 NTRK fusion was found in a KRASwt PDAC. BRCA1/2 somatic mutations, PIK3CA hotspot mutations, MDM2 amplifications and ERRB2 alterations were found similarly in both groups. We detected 5 KRAS G12C mutations. Patients harboring ESCAT alterations had a median OS of 25.0 versus 19.6 months for those without (HR 0.85, 95%CI (0.58 – 1.23), p=0.40). 66 patients (33.7%) were eligible to early-phase trials according to the molecular tumor board and 10 patients (5.1%) were effectively enrolled, with a range of time to progression between 22 days and 11 months.
Conclusions
Although actionable mutations are more prevalent in the KRASwt group, 16.3% of KRASm patients harbored ESCAT alterations, underlying the need for molecular profiling regardless of KRAS status.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
A. Italiano: Financial Interests, Personal, Advisory Board: Bayer, Roche, Philips, Chugai, GSK; Financial Interests, Institutional, Coordinating PI: Bayer, AstraZeneca, Roche, MSD, Ipsen, Merck. L. Blouin: Financial Interests, Personal, Other: AstraZeneca. S. Cousin: Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, Pfizer, BMS, Novartis, AbbVie; Financial Interests, Personal, Principal Investigator: MSD, BMS, Sanofi, AbbVie, Roche. S. Pernot: Financial Interests, Personal, Invited Speaker: Bayer, Amgen, Pierre Fabre; Financial Interests, Personal, Advisory Board: MSD, BMS, Servier, Merck. All other authors have declared no conflicts of interest.
Resources from the same session
1665P - Prognostic impact of diabetes and antidiabetic medication in pancreatic cancer patients
Presenter: Alexander Friedrich
Session: Poster session 22
1667P - Clinical and molecular features of young onset pancreatic adenocarcinoma
Presenter: Maxime Remond
Session: Poster session 22
1668P - Prevalence and management of pancreatic ductal adenocarcinoma (PDAC) over a decade in France: A population-based study
Presenter: Léo Mas
Session: Poster session 22
1670P - Tumoral and non-tumoral thrombosis associated with pancreatic ductal adenocarcinoma (PDAC): Survival impact, assessment of predictive scales and rethrombosis
Presenter: Alejandra Cardozo
Session: Poster session 22
1671P - Treatment patterns and efficacy in patients (pt) with pancreatic cancer (PC) from the Spanish RETUD registry
Presenter: Teresa Macarulla
Session: Poster session 22
1673P - Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study
Presenter: Sofie Olsson Hau
Session: Poster session 22
1674P - VILP registry of patients with metastatic pancreatic cancer treated with pegylated liposomal irinotecan plus 5-fluoroucil and leucovorin in the Czech Republic
Presenter: Stanislav Batko
Session: Poster session 22
1675P - Diagnostic performance of blood-based DNA methylation assay using epigenetic-specific peptide nucleic acid in pancreatic adenocarcinoma
Presenter: Hongsik Kim
Session: Poster session 22
1676P - Clinical outcomes of first-line chemotherapy in locally advanced and metastatic pancreatic adenocarcinoma patients: Real-world experience
Presenter: Nunticha Umpawan
Session: Poster session 22